Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
Natera (NASDAQ:NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $250.00 to $260.00. They now have an "overweight" rating on the stock.
Natera (NASDAQ:NTRA) was given a new $205.00 price target on by analysts at Wells Fargo & Company.
Natera (NASDAQ:NTRA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.